University of Utah Health

Clues to COVID-19 Complications Come from NET-like Inflammatory Response

29-Jun-2020 10:35 AM EDT, by University of Utah Health

Newswise — SALT LAKE CITY – An overactive defense response may lead to increased blood clotting, disease severity, and death from COVID-19. A phenomenon called NETosis—in which infection-fighting cells emit a web-like substance to trap invading viruses—is part of an immune response that becomes increasingly hyperactive in people on ventilators and people who die from the disease.

A team led by University of Utah Health and PEEL Therapeutics, in collaboration with Cold Spring Harbor Laboratory and Weill Cornell Medicine, report the findings in a new study published in the journal, Blood.

“This study tells us about a potential mechanism for lung injury in COVID-19 that had not previously been recognized as a possible target for treatment,” says Elizabeth Middleton, M.D., the study’s first author and a critical care specialist at U of U Health.

The investigation also reports that a naturally occurring protein—originally found in umbilical cord blood—quiets this NET immune response in laboratory experiments, potentially opening new avenues for treatment.

It is estimated that up to 10% of people with COVID-19 become critically ill with respiratory distress. Causes of lung damage are a subject of intense investigation, and increasing evidence demonstrates that increased blood clotting may lead to complications caused by the disease. 

Middleton, U of U Health physician-scientists and co-senior authors Christian Con Yost, M.D. and Joshua Schiffman, M.D., and colleagues, took a closer look to see if a specific immune response, called NETosis, could be involved.

As part of an immune response, white blood cells release web-like Neutrophil Extracellular Traps (NETs) to capture and kill pathogens. While typically beneficial, Yost had previously shown that overactive NETs exacerbate certain illnesses. In conditions such as overwhelming infection, NETs can clog blood vessels and lead to inflammatory tissue damage.

To determine whether NETs could be responsible for complications seen in COVID-19, the team examined plasma from 33 patients, along with tracheal aspirates from the lungs. They found that NET activity correlated with disease severity.

Patients on life support and those who died from COVID-19 had significantly more signs of NET activation than patients who were not as sick or who went on to recover. The NET immune response was lower still in healthy people. NET levels also tracked with a marker for blood-oxygen levels, an independent indicator of disease severity.

Similarly, plasma from sick patients was primed to launch the NET response. When examined in laboratory experiments, plasma from COVID-19 patients triggered white blood cells from healthy patients to shoot out 50 times as many NETs as cells exposed to plasma from otherwise healthy adults.

“This study may tell us that NET levels in the blood could potentially help predict disease severity and mortality in COVID-19,” says Yost, a physician-scientist at U of U Health. “Additional information is urgently needed in this pandemic regarding how to know which patient will fare better or worse.” Larger studies will need to be done to determine whether NETs could become a biomarker for COVID-19 severity. “Importantly, we think exaggerated NETs could be a cause of morbidity and mortality in COVID-19,” Yost says.

In support of the idea, collaborators at Cold Spring Harbor Laboratory showed that blood vessels in the lungs of deceased COVID-19 patients were dotted with clumps of NET-producing cells and a critical type of blood cell for clotting, the platelets. Another recent study from U of U Health showed that platelets become hyperactive during the disease. Investigations are now underway to determine whether NETs and platelets increase the risk for blood clotting and other clinical manifestations of COVID-19.

“In COVID-19, thrombosis is a major cause of death. So, our findings tell us that we should focus on understanding more about NETs’ role in clotting in COVID-19,” Mikala Egeblad, Ph.D., a cancer researcher from Cold Spring Harbor Laboratory, says. “Thrombosis is also a major cause of death in late stage cancer, where there also can be elevated NETs in the blood. Therefore, I think that what we learn from COVID-19 will help us with other diseases, including cancer.”

Additionally, laboratory experiments showed that a small protein found in umbilical cord blood of newborn babies, called neonatal NET Inhibitory Factor (nNIF), quiets the hyperactive NET response in white blood cells treated with COVID-19 patient plasma. This peptide is thought to protect babies from harmful inflammation early in life, explains Schiffman, CEO of PEEL Therapeutics. His company is now evaluating whether the protein could become the basis for a clinical treatment.

“Newborns babies have a natural therapeutic in their blood to protect against these same inflammatory events that we think could be killing COVID-19 patients,” Schiffman says. “This targeted approach to stopping NETs may be more effective with less side effects than some other drugs being tested now in COVID-19 patients that block the entire immune system­­­­.”

# # #

The research was carried out in collaboration with PEEL Therapeutics, Cold Spring Harbor Laboratory, New York Presbyterian Hospital, and Weill Cornell Medicine and published as “Neutrophil Extracellular Traps (NETs) Contribute to Immunothrombosis in COVID-19 Acute Respiratory Distress Syndrome” on June 29, 2020, in Blood.

Support for the work came from the National Institutes of Health, University of Utah Health’s 3i Initiative, Fonds voor Wetenschappelijk Onderzoek Vlaanderen FWO, Animal Cancer Foundation, Soccer for Hope Foundation, Closer to Cure Foundation, PEEL Therapeutics, Inc., William C. and Joyce C. O’Neill Charitable Trust, the Linartz-Meier Family Foundation, and the U.S. Department of Veterans Affairs.

Disclosure of conflicts of interest: The research was carried out with funding from PEEL Therapeutics, Inc., co-authors Abegglen and Iovino are consultants for and share option holders of PEEL Therapeutics, Inc., Schiffman and co-author Caulin are employed by and share option holders of PEEL Therapeutics, Inc. Yost authors a U.S. patent held by the University of Utah for the use of NET-inhibitory peptides for which PEEL Therapeutics Inc., holds the exclusive license.

About University of Utah Health

University of Utah Health provides leading-edge and compassionate medicine for a referral area that encompasses 10% of the U.S., including Idaho, Wyoming, Montana and much of Nevada. A hub for health sciences research and education in the region, U of U Health has a $373 million research enterprise and trains the majority of Utah’s physicians, including more than 1,250 health care providers each year at its Schools of Medicine and Dentistry and Colleges of Nursing, Pharmacy and Health. With more than 20,000 employees, the system includes 12 community clinics and four hospitals. For ten straight years, U of U Health has ranked among the top 10 U.S. academic medical centers in the Vizient Quality and Accountability Study. 

PEEL Therapeutics, Inc.

PEEL Therapeutics, Inc. is an emerging biotech that delivers evolution-inspired medicines to improve patient lives. The PEEL pipeline originates from assets inspired by the evolution of elephants, plants and humans for the treatment of cancer and inflammatory diseases, including COVID-19.

About Cold Spring Harbor Laboratory Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,100 people including 600 scientists, students and technicians. For more information, visit www.cshl.edu.

 

 

 

 

 

 

 

 

 

 

 

SEE ORIGINAL STUDY

MEDIA CONTACT
Register for reporter access to contact details
CITATIONS

Blood




Filters close

Showing results

110 of 2482
Released: 7-Jul-2020 5:25 PM EDT
Lung physiology and immune function in children could be protecting them from severe COVID-19
University of Texas Health Science Center at Houston

Differences in lung physiology and immune function in children could be why they are more often spared from severe illness associated with COVID-19 than adults, according to pediatric and adult physicians at UTHealth and Baylor College of Medicine, who teamed up to investigate the disparity.

Newswise: ACI Launches “Healthy Returns”: New Toolkit Contains Important Cleaning, Hygiene Reminders for Reopened Businesses and Offices
Released: 7-Jul-2020 5:15 PM EDT
ACI Launches “Healthy Returns”: New Toolkit Contains Important Cleaning, Hygiene Reminders for Reopened Businesses and Offices
American Cleaning Institute

As communities across the nation begin the reopening process stemming from the coronavirus (COVID-19) pandemic, the American Cleaning Institute (ACI) announced the roll-out of Healthy Returns, a free online toolkit for small businesses and offices containing concise, easy to understand reminders on hygiene, cleaning and disinfecting that are crucial to keeping the workplace healthy and safe.

access_time Embargo lifts in 2 days
Embargo will expire: 10-Jul-2020 1:00 AM EDT Released to reporters: 7-Jul-2020 3:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 10-Jul-2020 1:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-Jul-2020 2:45 PM EDT
COVID-19 in Patients Who Have Received Kidney Transplants or Are Undergoing Dialysis
American Society of Nephrology (ASN)

• A recent study found that most kidney transplant recipients with COVID-19 do not need to be hospitalized. • Another study found that patients on dialysis who develop COVID-19 may have symptoms that are different from other patients with the infectious disease.

Released: 7-Jul-2020 2:05 PM EDT
Law clinic wins access to COVID-19 race data
Cornell University

The First Amendment Clinic at Cornell Law School, working on behalf of its client, The New York Times, helped secure the release of previously unseen data that provides the most detailed look yet at nearly 1.5 million American coronavirus patients from 974 counties across the country.

Released: 7-Jul-2020 2:00 PM EDT
Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors (PPIs)
American College of Gastroenterology (ACG)

Findings from an online survey of more than 53,000 American adults suggest that using heartburn medications known as proton pump inhibitors (PPIs) once or twice daily significantly increases the odds of a positive test for COVID-19 compared to those who do not take PPIs. This research appeared online July 7, 2020 in pre-print format in The American Journal of Gastroenterology.

Released: 7-Jul-2020 1:40 PM EDT
COVID-related discrimination disproportionately impacts racial minorities, study shows
University of Southern California (USC)

Discrimination against people thought to be infected with coronavirus was experienced by a rising number of United States residents, particularly racial minorities, in the early stages of the COVID-19 pandemic, according to a new study from the USC Dornsife College of Letters, Arts and Sciences.

Newswise: 236726_web.jpg
Released: 7-Jul-2020 1:10 PM EDT
A chemical cocktail of air pollution in Beijing, China during COVID-19 outbreak
Institute of Atmospheric Physics, Chinese Academy of Sciences

The novel coronavirus disease (COVID-19) spreads rapidly around the world, and has limited people's outdoor activities substantially.

Released: 7-Jul-2020 12:50 PM EDT
Remdesivir can save more lives where ICUs are overwhelmed
Boston University School of Medicine

Amid news that the United States has bought up virtually the entire global supply of remdesivir, a new Boston University School of Public Health (BUSPH) study outlines how the drug could save lives in countries with less hospital capacity, such as South Africa, where COVID-19 is beginning to overwhelm intensive care units (ICUs).

Newswise: Cedars-Sinai Named Age-Friendly Health System
Released: 7-Jul-2020 12:40 PM EDT
Cedars-Sinai Named Age-Friendly Health System
Cedars-Sinai

Shortly after COVID-19 was declared a pandemic, more than 450 older adults learned their weekly exercise classes offered through the Cedars-Sinai Geriatrics Program were on hold. But under the quick-thinking direction of geriatrician Allison Moser Mays, MD, the program pivoted, creating a way for seniors to access live classes over Zoom from the comfort of their homes. The online format has proved especially popular.


Showing results

110 of 2482

close
1.41714